Ѫ¹ÜÑ×Ö¢·´Ó¦,vascular inflammationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þÑõ»¯Ì¼½áºÏÁ¦,carbon dioxide combining powerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃÚÄòÉúֳϵͳ¼²²¡/΢ÉúÎïѧ,urogenital diseases/microbiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µâ131,iodine l31Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÐЧÒȵºËØ,Isophane InsulinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ñÁÐßÁ຿ØÊÍÆ¬,Glipizide Controlled-Rrelease TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ó¼××´ÏÙËØÄÆÆ¬,Levothyroxine Sodium TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÆÏÌÑÌǸººÉ,glucose loadÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¡·Ê´ó,muscular hypertrophyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¡ÒòÖÎÁÆ,etiological treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»îÐÔÑõ×ÔÓÉ»ù(ROS),Reactive Oxygen Species (ROS)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉøÍ¸ÐÔÅòÕÍ,osmotic expansionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉöСÇò·Ê´ó,Glomerular hypertrophyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Û·ÉÆ,ShanshanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ËÀÍö¹ØÏµ,Death relationshipÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ»·×æÏ¸°û,Circulating progenitor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÆ¤Ï¸°û΢¿ÅÁ£,endothelial microparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÒò×ÓÐźÅתµ¼ÒÖÖÆÒò×Ó3,suppressor of cytokine signaling 3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÛÄÚ×¢Éä,intraocular injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡ÖÜΧѪ¹Ü²¡,Diabetic Peripheral Vascular DiseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½Ó´¥ÐÔÈÈÍ´ÓÕ·¢µçλ,Contact heat evoked potentialÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾½Þ×´ÌåÆ½Ì¹²¿²£Á§ÌåÇиîÊõ,pars plana vitrectomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ë«ÄÜXÏß²âÁ¿,Dual-energy X-ray absorptiometry(DXA)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
RF/6Aϸ°û,RF/6A cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒȵºËØÆô¶¯×Ó,Insulin promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·À¿ØÍøÂç,prevention and control networkÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
AT_4ÊÜÌå,AT_4 receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô¤»ìÒȵºËØ,premixed insulinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
CDK11p58»ùÒò,CDK11p58 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˼××´ÅÔÏÙ¼¤ËØ(1-34)Ƭ¶Î,Human parathyroid hormone(1-34) fragmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉöÉÏÏÙÆ¤Öʹ¦ÄܼõÍË,adrenocortical insufficiencyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²Ç°ÆÚ,Preclinical phaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
СÏËάÉñ¾²¡,Small Fiber neuropathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ßÒȵºËØ-ÕýѪÌÇǯ¼Ð,hyperinsulinemic-euglycemic clampÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¨Á¿CT²â¶¨·¨,Quantitative Computed TomographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èâ¶¾¼îÖ¬õ£×ªÒÆÃ¸1,Acyl-CoA oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹«°²¼à¹Ü³¡Ëù,the public security supervision and management areasÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶à·¢ÐÔ¼¡Ñ×Ñù×ÛºÏÕ÷,polymyositis-like syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
NADPÑõ»¯Ã¸,NADPH oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼××´ÏÙËØ/ÖÎÁÆÓ¦ÓÃ,thyroxine/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇÖÊÊèËÉÐÔ×µÌåѹËõ¹ÇÕÛ,osteoporotic vertebral compressive fractureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
С×éÖÎÁÆ,Group interventionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇ´úлָ±ê,Metabolic indicesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Âϸ°ûµòÍö,¦Â-cell apoptosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»úеʹãÐ,Mechanical thresholdÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÆ¤Ï¸°ûÒ»Ñõ»¯µªºÏø,Endothelial nitric oxide synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÛÏ´¼¿¹Ñõ»¯Îï(ø),thiol antioxidantsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±Ç¾Ò¼Ùµ¥°û¾ú,Pseudomonas malleiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡Ç°ÆÚ״̬,Prediabetic stateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¹ÔÐÍÑÌõ£°·ÏÙàÑßʶþºËÜÕËáÁ×ËáÑõ»¯Ã¸,Nicotinamide adenine dinucleotide phosphate oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼××´ÏÙ²¡,thyroid diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏÂÖ«´óѪ¹Ü²¡±ä,Macroangiopathy of lower limbÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
2ÐÍÌÇÄò²¡ÊÓÍøÄ¤²¡±ä,type 2 diabetic retinopathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö¬·¾ËáºÏ³Éø(FAS),fatty acid synthase(FAS)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÊкóÆÀ¼Û,post-marketed evaluationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½µÑªÌÇÒ©/ÖÎÁÆÓ¦ÓÃ,Hypoglycemic Agents/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ç⻯´ó¶¹Á×Ö¬,hydrogenated soybean phosphatidylcholineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿Õ¸¹Ìǵ÷½ÚÊÜËð,Impaired fasting glucoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ÇÂå,William Edgar GeilÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐäÖÊÖØ¹¹,myocardial interstitial remodelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡¿ØÖÆÇé¿ö,Quality in evaluating diabetes controlÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ֬ÐÔ×´,blood-fat traitÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿Ú·þ½µÌÇÒ©Îï,Oral hypoglycemic agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¡´¼¼ÓÑõø,myoinositol oxygenaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¥ÏòÇíÖ¬À©É¢,single immunodiffusion testÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
É£Òø½µÌǽºÄÒ,Sangyin capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ê¿×¼õѹÊõ,drilling decompressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂýÐÔ˯Ãß°þ¶á,Chronic sleep deprivationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µÍѪÌÇÉú³ÉÖ¸Êý,low glycemic-indexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÀËã·¨,estimation methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¨¹Ì´¼ºÏ³ÉÒÖÖÆ¼Á,cholesterol-synthesizing inhabitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÔ¸ÉÌý¾õÓÕ·¢µçλÂý³É·Ö,slow component of brainstem auditory evoked potentialsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂýÐÔ¼ÙÐÔ³¦¹£×è,Chronic intestinal pseudo-obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¹Éö½¡Æ¢ÖÐÒ©,Chinese herbs for reinforcing Shen and strenghening PiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡ÔçÆÚÉöËðÉË,Early diabetic kidney injury Urinary microalbuminuriaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÆÖ²ºóÌÇÄò²¡,post-transplantation diabetes mellitusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡×ã/Ò©ÎïÁÆ·¨,diabetic foot/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éú³¤¼¤ËشٷÖÃÚËØÊÜÌå-1a»ùÒò,growth hormone secretagogue receptor-1a geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áúµ¨Ðº¸ÎƬ,Longdan Xiegan TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß·¢ÆÚ,the highest periodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉöÉÏÏÙÆ¤Öʹ¦ÄܼõÍËÖ¢,adrenal hypofunctionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ǰÁеضû(¿Ê±),Liop PGE1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾ø¾ÄêÏÞ,menopausal periodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
2ÐÍÌÇÄò²¡ÔçÆÚÉö²¡,type 2 diabetes and early signs of nephropathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö¬ÁªËØÊÜÌå-1,adiponectin receptor-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡²¡»ú,diabetes mellitus pathogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ìºÏÐÔ¸ß֬Ѫ֢,Compound hyperlipimiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
7-¶þ·úÑǼ׻ù-5,4'-¶þ¼×ÍéÑõ»ùÒì»ÆÍª,7-Difluoromethylyl-5,4'-Di-methoxyl isoflavoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌÇÄò²¡Éö²¡»¼Õß,Diabetic nephropathy patientÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÑÉïÆÚÌÇ´úлÒì³£,gestational abnormal glucose metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HBV¸ÐȾģʽ,HBV infection typeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¥²à̽²é,Unilateral explorationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²ÕïÖηÖÎö,analysis of clinical managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÇÊÖÊõ·½·¨,Nonsurgical techniqueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²ÍºóÔ˶¯,postprandial exerciseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»îѪ½µÌǽºÄÒ,Huoxuejiangtang CapsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ÌÒõÈóÔï·¨,method of nourishing yin and moistering aridÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Õ³¸½¹¦ÄÜ,adhesive functionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ßÒȵºËØ-ÕýÆÏÌÑÌÇǯ¼Ð¼¼Êõ,hyperinsulinemic-euglycemic clampÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶þÌÇ×é³É,disaccharide compositionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|